The third time is not the charm for Hengrui Pharma and Elevar Therapeutics’ star-crossed combination of camrelizumab and ...
Amid restructuring efforts, Bayer has addressed its need for a capital infusion in pharma under a deal to secure 3 billion ...
Sanofi has scored FDA approval for its subcutaneous version of Sarclisa, giving the multiple myeloma treatment a potential ...
In the two weeks before and after Independence Day in the U.S., AstraZeneca signed potential billion-dollar licensing deals ...
This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the ...
After several months of AbbVie leading pharma’s monthly ad spend, Johnson & Johnson is back as Tremfya topped June’s rankings ...
Unexpectedly catapulted into global fame as a COVID-19 vaccine maker, BioNTech is on the verge of returning to its oncology ...
Aiming to streamline the compensation process for people claiming harm from COVID-19 vaccines, Robert F. | Aiming to ...
The transaction's two focuses, Palsonify and atumelnant, have combined peak sales potential of more than $5 billion, Vertex ...
The CARDIO-TTRansform study did not meet its primary endpoint, which centered on reducing cardiovascular deaths or recurrent ...
When launching a drug as big as semaglutide, even as a generic, the market expectations are immense, and any fumble on the ...
In a first for the neurotoxin market, Ipsen announced Thursday that its Dysport has hit the goals in two phase 3 trials for the prevention of both episodic and chronic migraines. While AbbVie’s market ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results